Background: Genomewide association studies have found significant genetic correlations among many neuropsychiatric disorders. In contrast, we know much less about the degree to which structural brain alterations are similar among disorders and, if so, the degree to which such similarities have a genetic etiology.
Introduction
Neuropsychiatric disorders have substantial heritability, as shown by many studies of twins and families (1) . Genomewide association studies (GWAS) have shown that common genetic variants account for some of this heritability, and that some of this heritability is shared across neuropsychiatric disorders (2) (3) (4) (5) . The genetic overlap across disorders may partly explain why these disorders tend to co-occur with one another in both clinical and community samples (6) . Subcortical brain volumes and cortical thickness/surface area dynamically change from early development through adulthood and old age. A study of the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) Plasticity Working Group reported that changes in structural magnetic resonance imaging (sMRI) phenotypes have heritabilities ranging from 5% for pallidum to 42% for cerebellar gray matter (7) . Heritability estimates of change rates were age-related and generally higher in adults than in children, probably due to an increasing influence of genetic factors with age (7) . ENIGMA sMRI studies of different psychiatric and neurological disorders further characterized MRI-derived phenotypes that can be used to assess heritability (reviewed in 8).
ENIGMA has also reported significant case vs. control differences in sMRI phenotypes for: attention-deficit/hyperactivity disorder (ADHD) (9, 10) , autism spectrum disorder (ASD) (11) , bipolar disorder (BD) (12, 13) , common epilepsy syndromes (14) , major depressive disorder (MDD) (15, 16) , obsessive compulsive disorder (OCD) (17, 18) and schizophrenia (SCZ) (19, 20) . Each of these disorders shows a pattern of what we have termed selective brain region vulnerability (SBRV) (21, 22) . By this, we mean that some brain regions may be more vulnerable to the genetic and environmental risk factors associated with each disorder. If that is true, some brain regions should show volumetric case-control differences and others not, and this should be correlated among disorders that share risk factors. To date, there has been no cross-disorder study of SBRV for the disorders for which such differences have previously been reported in the ENIGMA consortium. Given that pairs of ENIGMA disorders show a range of genetic correlations, studying SBRV across disorders should supply clues as to the degree to which common genetic variants explain SBRV in these disorders. Because SBRV may reflect differential vulnerability of cells to stresses caused by environmental exposures and/or genetic predisposition, clarifying the extent and etiology of SBRV could have implications for therapeutic developments. If genetic risk factors are involved in SBRV, we hypothesized that SBRV would be correlated among disorders and that the magnitude of these correlations would mirror the magnitude of their genetic correlations from GWAS studies.
Methods

Collection of structural neuroimaging summary statistics
Summary statistics from ENIGMA structural neuroimaging studies were collected from 12 multi-site analyses published by the ENIGMA Consortium for the following neuropsychiatric disorders: ADHD (9, 10), ASD (11), BD (12, 13) , epilepsy (14) , MDD (15, 16) , OCD (17, 18) , and SCZ (19, 20) . The ADHD and ASD samples comprised both youth and adults. The other samples comprised adults only. The "epilepsy" cohort comprised temporal lobe epilepsy, genetic generalized epilepsy, and extra temporal epilepsy. We analyzed 7 subcortical and 34 cortical regions (total of 41 brain regions; the mean of left and right structures) that were included in the above specified ENIGMA studies. We extracted the covariate-adjusted Cohen's D standardized mean differences (SMDs) denoting the case versus unaffected comparison subject differences in subcortical volume and cortical thickness/surface area measures. The covariates used in these studies adjusted SMDs for several covariates as indicated in Supplemental Table 1 .
Collection of GWAS results among neuropsychiatric disorders
Publicly available summary statistics from GWAS were downloaded from the Psychiatric Genomics Consortium (PCG) website (https://www.med.unc.edu/pgc/results-and-downloads/) with the exception of GWAS results for MDD coming from an online resource hosted by the University of Edinburgh (http://dx.doi.org/10.7488/ds/2458) and of GWAS results for epilepsy coming from the online Epilepsy Genetic Association Database (epiGAD) (http://www.epigad.org/gwas_ilae2018_16loci.html). Presented in Supplementary Table 2 are the numbers of affected cases and unaffected control participants included in each GWAS.
Note, the full meta-analysis GWAS of MDD that included data from 23andMe was not available for public release, thus we used the meta-analysis that combined results from the PGC cohorts and UK Biobank.
Genetic and sMRI phenotype correlations among neuropsychiatric disorders
Linkage disequilibrium (LD)-score regression, a popular approach designed to analyze summary statistics from GWAS, was used to quantify the amount of shared genetic heritability, or genetic correlation (r g), existing between pairs of neuropsychiatric disorders, considering HapMap3 LD-scores (23) .For these analyses, the largest and latest GWAS available for each neuropsychiatric disorder was selected and filtered to exclude markers with INFO<0.90 or within the MHC region (hg19:chr6:25-35Mb) ( Supplementary Table 1 ).
To derive an estimate of the degree to which sMRI phenotypes were similar among disorders, we computed pairwise Pearson's correlation coefficients between the Cohen's D SMDs for each pair of disorders. We then used Pearson's correlation to estimate, whether the genetic correlations for each disorder covaried with the sMRI phenotype correlations. In a leave-one-out analysis, we iteratively excluded one pair of disorder correlations from the set and recalculated Pearson's correlation coefficients to determine whether correlations were driven by any pair of disorders. We used classical multidimensional scaling (MDS) with correlation as the distance measure to visualize and help interpret the sMRI phenotype correlations. MDS summarizes the correlations among disorders in their SMDs by plotting them in a lowdimensional space for which the distance between disorders is proportional to their correlations.
Binomial sign tests were used to determine whether the number of disorders showing the same direction of effect in the sMRI phenotypes was greater than expected by chance (null probability of 50%). Per brain region, we performed Cochran's Q test implemented in the R package metafor (v.2.1-0) to determine whether variability among Cohen's D values was greater than expected by chance. All statistical analyses were performed with R version 3.5.2 (R Core Team, 2018), except for multidimensional scaling, for which we used STATA15 (24) . We adjusted for repeated correlation tests using the Bonferroni procedure. Correlations showing a Bonferroni-adjusted p < 0.05 were considered significant (threshold p = 0.00227).
Results
Sample demographics for the twelve studies by the ENIGMA Consortium on structural brain abnormalities in neuropsychiatric disorders are presented in Table 1 . regions of interest varying degrees of heterogeneity were noted in terms of discrepancy of signs of Cohen's D. For example, individuals with ASD showed a slightly thicker cortex in the rostral middle frontal gyrus, individuals with ADHD showed no difference, and all other disorders showed a thinner cortex in this region compared to controls.
Case-control differences in subcortical volume and cortical surface area and thickness within neuropsychiatric disorders
sMRI phenotype correlations among neuropsychiatric disorders
For each pair of disorders, we computed the Pearson correlation between their sMRI phenotypes listed in Figure 1 . These are listed in Table 2 , sorted by the magnitude of the correlation. The highest positive correlation was between SCZ and BD (r=0.81, df = 73, p<1.3×10 -18 , Bonferroni p=2.38×10 -17 ). SCZ was also positively correlated with OCD (r=0.65, df = 72, p=5.5×10 -10 , Bonferroni p=1.2×10 -8 ), ASD (r = 0.36, df = 73, p = 0.0014, Bonferroni p = 0.03), and MDD (r=0.57, df = 73, p=5.5×10 -8 , Bonferroni p=1.2×10 -6 ). MDD was positively correlated with BD (r=0.68, df = 73, p=1.2×10 -11 , Bonferroni p=2.5×10 -10 ) and OCD (r=0.46, df = 72, p=3.3×10 -5 , Bonferroni p=6.9×10 -4 ). BD was positively correlated with OCD (r=0.50, df = 72, p=4.7×10 -6 , Bonferroni p=9.9×10 -5 ) and ASD (r=0.38, df = 73, p=9.0×10 -4 , Bonferroni p = 0.02), and negatively correlated with ADHD (r=-0.53, df = 73, p=1.2×10 -6 , Bonferroni p=2.5×10 -5 ).
There were a few additional nominally significant negative correlations, which did not survive multiple testing correction: MDD and epilepsy (r=-0.37, p=0.02), MDD and ADHD (r=-0.33, p=0.004), SCZ and ADHD (r=-0.32, p=0.005), ADHD and epilepsy (r=-0.36, p=0.02), and a positive correlation between MDD and ASD (r = 0.26, p = 0.02). captures variation that separates ADHD and ASD from the mood disorders and OCD. Figure 2d provides another view of the same data, which confirms that epilepsy is an outlier on dimension 2. 
Correlation of shared genetic heritability with brain structural correlation
Discussion
Our analysis of summary statistics from the ENIGMA ADHD, ASD, BD, MDD, OCD, SCZ and epilepsy Working Groups and the predominantly PGC case-control GWAS identified two novel findings. First, we found substantial correlations for some disorders in the pattern of sMRI case-control differences across subcortical and cortical regions that we postulate represent selective brain region vulnerability (SBRV). Second, these cross-disorder correlations in SBRV could partly be explained by the genetic correlations reported for these disorders from genomewide association studies (3).
The cross-disorder correlations in SBRV are intriguing because, like cross-disorder genetic correlations, they suggest that these disorders, to varying degrees, share aspects of their etiology and pathophysiology. Any interpretation of the cross-disorder sMRI correlations must keep in mind that, for all disorders, the case-control differences in sMRI measures are small ( Figure 1) . The largest Cohen's D values are only -0.5 for SCZ (19, 20) , -0.4 for epilepsy (14) , -0.3 for BD (12, 13) , -0.2 for ADHD (9, 10) and ASDs (11) , and -0.1 for MDD (15, 16) and OCD (17, 18) . These small case-control differences are consistent with results from GWAS and environmental risk studies, which speaks to the fact that the effects of common risk factors are, with some rare exceptions, individually small. Although it is conceivable that these small risks could accumulate to create a more dramatic pathophysiology in the brain, the ENIGMA data show that this is not the case for sMRI measures. Consistent with this finding, interindividual differences in neuroimaging account for only a small amount of the variance in symptom expression or behavioral measures of symptomatic or behavioral variance (25) .
The most prominent case-control differences in cortical thickness/surface area and subcortical volumes were observed for SCZ (19, 20) and BD (12, 13) . These disorders also had the highest sMRI phenotype correlations and both also showed strong sMRI phenotype correlations with MDD (15, 16) and OCD (17, 18) . As Figure 2 shows, these disorders clustered together in the three-dimensional configuration required to capture cross-disorder sMRI phenotype similarity. The high sMRI correlation between SCZ and BD is consistent with prior reports of sMRI similarities between the two disorders (26) . Moreover, a large body of literature reports substantial etiologic overlap between the two disorders (27) (28) (29) (30) (31) . Because of such data, the SCZ and BD have been described as sharing a continuum of etiology leading to psychotic (32), neurophysiological (32) and neurocognitive (33) symptoms. The ENPACT study (34) showed shared fronto-temporo-occipital grey matter volume deficits in the right hemisphere of two disorders. A systematic review of associations between functional MRI activity and polygenic risk for SCZ and BD (28) reported that genetic load for these disorders affects taskrelated recruitment of predominantly frontal lobe brain regions.
Many studies have reported that OCD can be a comorbid diagnosis with SCZ or that patients with SCZ can have OCD symptoms (35) (36) (37) (38) (39) (40) (41) (42) . Presented findings of a significant overlap in sMRI phenotypes along with the known SCZ/OCD genetic correlations suggests that more work should examine shared pathophysiologic features between these disorders and should assess the degree to which confounds, such as medication status or chronicity, might explain these results.
The sMRI phenotype correlations mirror, to some extent, the cross-disorder correlations from genomewide association studies. Figure 3 shows a modest, yet distinct, linear correlation between the sMRI phenotype and genetic correlations. In the upper right-hand section of the plot, we see disorders having high genetic and high sMRI correlations. These are SCZ/BD, SZ/MDD, BD/MDD, OCD/BD and OCD/MDD. The inclusion of MDD in this group is notable given that it is part of the bipolar diagnosis and often occurs comorbid with other disorders.
MDD also has a high genetic correlation with ADHD but a negative sMRI correlation, which makes that pair an outlier in Figure 3 .
In the lower left region of Figure 3 Our prior studies of SBRV in ADHD implicated the regulation of genes in apoptosis, autophagy and neurodevelopment pathways in ADHD (21, 22) . Neurodevelopmental pathways had also been implicated in the cross-disorder analysis of the Psychiatric Genomics Consortium (3), which suggests that cross-disorder similarities in these pathways may account for cross disorder similarities in SBRV.
Although we used data derived from very large samples (ENIGMA, iPSYCH and the PGC), several limitations moderate the strength of our conclusions. We inherit all the limitations of the constituent studies, but are further limited because we analyzed summary statistics, not the original data, which would require the sharing of individual subject level data, an ongoing effort among the ENIGMA disorder working groups. Thus, we cannot determine whether the possible use of controls shared among studies affected our results. It is also possible that some research participants were included in the genetic and sMRI data sets for the same disorder.
Another problem is that we could not address effects of medications or chronicity on brain structure. Furthermore, for some of the disorders, we could use youth and adult data, whereas for others only adult effect data were used. Because findings can differ substantially depending on the age range of the samples included (e.g., (9, 10, 17, 18) ), this might have influenced our findings. For these reasons, analyses of participant level data will be needed to address these issues to draw stronger and more detailed conclusions. We also did not have any longitudinal data available, which limits the ability to test hypotheses about shared and unique developmental trajectories among disorders.
Despite these limitations, we have documented cross-disorder correlations in SBRV as assessed by sMRI. These cross-disorder SBRV correlations are positively associated with the disorders' corresponding cross-disorder genetic correlations. This finding is a novel contribution worthy of further study. Our work supports conclusions from previous GWAS studies suggesting a partially shared etiology and pathophysiology among many disorders (2, 43) .
Disorders like SCZ and BD or ADHD and ASD, which are distinct in the diagnostic nomenclature, show significant overlap in etiology and pathophysiology. Further studies are needed to discern why brain regions are selectively affected by the risk factors that cause sMRI abnormalities and why these effects are correlated across disorders. Such studies may give insights into new treatment targets.
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